Fenofibrate in Dyslipidemia and Metformin-Controlled Diabetes
NCT ID: NCT00349128
Last Updated: 2007-09-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2/PHASE3
382 participants
INTERVENTIONAL
2004-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
fenofibrate and metformin combination (drug)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
20 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Solvay Pharmaceuticals
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Global Clinical Director Solvay
Role: STUDY_DIRECTOR
Solvay Pharmaceuticals
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Site 201
Katowice, , Poland
Site 203
Katowice, , Poland
Site 202
Warsaw, , Poland
Site 204
Zabrze, , Poland
Site 111
Dnipropetrovsk, , Ukraine
Site 113
Dnipropetrovsk, , Ukraine
Site 108
Kharkiv, , Ukraine
Site 109
Kharkiv, , Ukraine
Site 101
Kyiv, , Ukraine
Site 102
Kyiv, , Ukraine
Site 103
Kyiv, , Ukraine
Site 104
Kyiv, , Ukraine
Site 105
Kyiv, , Ukraine
Site 106
Kyiv, , Ukraine
Site 107
Kyiv, , Ukraine
Site 112
Zaporizhya, , Ukraine
Site 35
Acomb, , United Kingdom
Site 21
Atherstone, , United Kingdom
Site 14
Balsall Common, , United Kingdom
Site 32
Bangor, , United Kingdom
Site 23
Barry, , United Kingdom
Site 36
Basingstoke, , United Kingdom
Site 8
Bexhill-on-Sea, , United Kingdom
Site 20
Camberley, , United Kingdom
Site 22
Chesterfield, , United Kingdom
Site 10
Chippenham, , United Kingdom
Site 13
Coventry, , United Kingdom
Site 31
Doncaster, , United Kingdom
Site 15
Downpatrick, , United Kingdom
Site 17
Ely, , United Kingdom
Site 4
Ely, , United Kingdom
Site 11
Fife, , United Kingdom
Site 1
Frome, , United Kingdom
Site 16
Harrow, , United Kingdom
Site 5
Hastings, , United Kingdom
Site 26
Haverfordwest, , United Kingdom
Site 19
Keresley End, , United Kingdom
Site 9
Kingswood, , United Kingdom
Site 25
Newtownabbey, , United Kingdom
Site 33
Northampton, , United Kingdom
Site 28
Odiham, , United Kingdom
Site 3
Paignton, , United Kingdom
Site 12
Peterborough, , United Kingdom
Site 7
Randalstown, , United Kingdom
Site 27
Slough, , United Kingdom
Site 6
Soham, , United Kingdom
Site 2
South Glamorgan, , United Kingdom
Site 34
Stratford-upon-Avon, , United Kingdom
Site 29
Swindon, , United Kingdom
Site 30
Trowbridge, , United Kingdom
Site 18
Yaxley, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
C LF23-0121 03 01
Identifier Type: -
Identifier Source: org_study_id